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Effect of Previous Treatment with Aspirin or
Nitrates on the Clinical Manifestation of Acute
Coronary Syndrome
David Garcia-Dorado, Juan Oliveras, Pilar Tornos, Gaieta Permanyer,
Antonia Sam bola, Maite Santos, Pierre Theroux, J. Soler-Soler. Hospital Vall
d'Hebron, Barcelona, Spain; Montreal Heart Institute, Canada
Aspirin (ASA) and nitrates inhibit platelet aggregation by different mecha-
nisms, and it has been suggested that their antiaggregating effects could be
additive. To analyze the influence of previous treatment with aspirin (ASA) or
nitrates on the clinical manifestations of acute coronary syndrome, a series
of 323 pts consecutively admitted to the cardiology emergency room with
unstable angina (UA) or acute myocardial infarction (MI). and with a previous
history of coronary heart disease, was prospectively characterized.
A standardized questionnaire was used to determine risk factors, previous
cardiac history, and use of drugs preceding the index event. Previous use was
defined as any dose of ASA during the week before, or of oral or transdermal
nitrates during the 24 h before the onset of the event.
The final diagnosis by serial ECGs and enzyme determinations, was UA
in 226 pts, and MI in 95. Fifty-one pts had received previous treatment with
ASA but not with nitrates, 51 had received nitrates but not ASA, 105 had
received both drugs and 94 had received neither ASA nor nitrates. The final
diagnosis was MI in 12 (24%) pts who had received ASA, 12 (24%) in pts
who had received nitrates, 21 (20%) in pts on both ASA and nitrates, and
43 (46%) in those receiving neither ASA nor nitrates (p ~ 0.0003). Multiple
logistic regression analysis identified prior ASA and prior nitrates, but not
age, sex, risk factors, previous myocardial infarction, or prior treatment with
betablockers or Ca++ entry blockers, as independent predictors of UA vs
MI. The regression model did not detect any interaction between ASA and
nitrates.
These results suggest that both prior treatment with ASA and with nitrates
modify the clinical manifestations of acute ischemic syndrome reducing its
severity, and that these effects are compatible with their effects being addi-
tive.
Medical treatment consisting of beta-blockers (BB), calcium blockers (CB)
and nitrates (N) is recommended and frequently employed in patients (pts)
before and during hospitalization with unstable coronary syndromes (UA).
but the benefit is unclear in the setting of combined aspirin and anticoagu-
lation. To study the effect of each of these drugs on in-hospital events, we
examined 410 pts with UA entered in the TIMI-7 trial in which all pts received
aspirin and one of 4 doses of the direct thrombin inhibitor, hirulog.
Prior to hospitalization, 44% of pts received BB, 50% CB, and 51 % N. Com-
pared to pts not on these drugs, pts on each medication were older (average
62 vs 59 yrs). had a higher incidence of prior MI(BB, CB, N), revascularization
(CB, N), hypertension (BB, CB, N). and diabetes (CB, N), and were more likely
to be receiving aspirin IBB, CB, N). Stepwise regression showed that prior
treatment with any of the 3 drugs was not predictive of in-hospital death, MI
or documented recurrent ischemia.
After enrollment and during hospitalization, 71 % of pts received BB, 66%
CB, and 95% N at the discretion of their physicians. The in-hospital occur-
rence of death (4%). Ml (6%), recurrent ischemia (8%) or their combined
incidence (14%), the number or severity of in-hospital anginal episodes, or
the incidence of catheterization (64%) or revascularization (38%) were not
significantly related to treatment with any of the 3 drugs. The combined inci-
dence of in-hospital death, MI or recurrent ischemia was best predicted by
the presence of ECG changes on admission (multivariate adjusted odds ratio
[OR] 2.83, p < 0.01) and advanced age (OR 2.38, P < 0.01) but not by other
factors.
Prior or newly instituted anti-ischemic medical therapy, administered in a
nonrandomized fashion in this trial, may have contributed to clinical stability.
During hospitalization for UA, aspirin and anticoagulation playa primary role
in determining clinical outcome.
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What Beyond Aspirin and Anticoagulation
Improves Outcome in Unstable Angina? Effect of
Medical Therapy
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Joe Massaro, Sebastian 1. Palmeri, Judith S. Hochman, Carolyn 1. McCabe,
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containing (mM) 2'-deoxyglucose (20), NaCN (1). Na-lactate (20). K+ (10) at
pHo 6.6 (3rC). Changes of myocyte length were monitored with an optical-
video edge recording system, and hypercontracture was used as the index
of irreversible cell injury (cell death). Results: PC (2 min ischemia followed by
15 min reperfusion) significantly reduced cell injury resulting from the subse-
quentextended ischemia (10 min) and reperfusion (15 min), as indicated bya
reduction in cell death from 67 ± 6% (cells ~ 110, control) to 29 ± 5% (cells
= 101, with PC, p < 0.001). PC-induced cardioprotection was only partially
blocked by the maximally effective dose of the adenosine A, -receptor antag-
onist DPCPX (1 00 nM) Icell death = 43 ± 3%, cells = 88, P < 0.05 vs control)
but completely blocked by either the combination of DPCPX (100 nM) with
the adenosine A3-receptor antagonist BW A1433 (1 /LM) (cell death ~ 64 ±
4%; cells = 82; P = NS vs control). or the non-selective adenosine receptor
antagonist, 8-SPT (100 /LM) (cell death = 59 ± 5%; cells ~ 86; P = NS vs
control). as shown in the Figure. Conclusion: PC-induced cardioprotection is
mediated in part through the activation of adenosine A3-receptors.
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Myocardial Protection by Na+IH+ Exchange
Inhibition in Ischemic, Reperfused Porcine
Hearts
Hermann H. Klein, Sibylle Pich, Rainer M. Bohle, Jutta Wollenweber,
Klaus Nebendahl. Universities ofMarburg and G6ttingen, Fed. Rep. of Germany
Myocardial and Coronary Vascular Protection
After Coronary Occlusion and Reperfusion by
Selective Sinoatrial Node Inhibition
Roger Williams, Wilmer W. Nichols, Liying Chen, Michael S. Stalvey, Linda
V. Thompson, Tiffany D. Boyd, Jawahar L. Mehta, Carl J. Pepine. University of
Florida and VA Medical Cente" Gainesville, FL
The protective effect of the Na+/H+ exchange inhibitor HOE 694 was tested
in porcine hearts subjected to 45 min of regional ischemia and 24 h of reper-
fusion. The compound (3 mg/kg) was intravenously injected in 6 pigs each ei-
ther 10 min before ischemia (group A) or 10 min before reperfusion (group B).
Six animals served as controls. Apart from the main end-points, infarct size
and regional systolic shortening, the effect of HOE 694 on global hemody-
namic parameters which included coronary blood flow and coronary venous
oxygen saturation was evaluated. Although the Na+IH+ exchange inhibitor
did not affect global hemodynamics, preischemic treatment with HOE 694
decreased infarct size from 65 ± 18% (control group) to 12 ± 9% (p < 0.01)
and improved systolic shortening from 8 ± 6% (control group) to 28 ± 9%
P < 0.02). In addition, increase in heart rate and myocardial contracture dur-
ing early reperfusion were significantly attenuated in group A. Treatment of
group B did not exhibit protective effects.
Conclusion: Na+/H+ exchange inhibition is a very protective means in my-
ocardial ischemia and reperfusion when administered before ischemia. In
this model, it was ineffective when given before reperfusion.
Improved regional myocardial function and abnormal flow reserve resulting
from myocardial ischemic injury has been observed with ,II-blockade. To de-
termine if heart rate reduction alone would offer similar protection, anes-
thetized dogs were subjected to left anterior descending (LAD) occlusion
and given a selective SA node inhibitor (ZD7288 0.5 mg/kg, n = 5 or buffer,
n = 7). After 1 hour of occlusion they were reperfused. ZD7288 decreased
heart rate by 28 ± 2% (153 ± 14 to 120 ± 11 bpm, p < 0.05) at 1 hr after
reperfusion. In buffer-treated dogs, peak reactive hyperemic (RH) response
after 20 sec LAD occlusion, (index of coronary flow reserve). fell from 276 ±
22% to 135 ± 18% and LAD regional shortening fraction (SF, by ultrasonic
crystals) decreased from 9.7 ± 1.5% to 0.6 ± 0.1 % after reperfusion (both,
p < 0.001). In ZD7288-treated dogs, peak RH and SF after reperfusion (227
± 19% and 4.2 ± 0.8%, respectively) were preserved (p < 0.05) vs buffer-
treated dogs. Despite similar area of left ventricular (LV) at risk, infarct area
(as % of LV). was also smaller in ZD7288-treated vs. buffer-treated dogs (14.0
± 0.5 vs 23.0 ± 1.10%, P < 0.05). Heart rate was maintained constant with
atrial pacing in five other ZD7288-treated dogs and neither peak RH or SF
were preserved compared with buffer-treated dogs.
Thus, selective SA node inhibition alone, induced after coronary occlusion,
results in myocardial and coronary vascular protection after reperfusion. Se-
lective SA node inhibition may have clinical utility in acute myocardial pa-
tients who are not candidates for beta blockers.
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